|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
51952031
???header.onlineuser??? :
931
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"papavassilis c"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-10-22T07:28:03Z |
Secukinumab in plaque psoriasis - Results of two phase 3 trials
|
Karpov A.; Hampele I.; Notter M.; Salko T.; Tyring S.; Langley R.G.; Elewski B.E.; Lebwohl M.; Reich K.; Griffiths C.E.M.; Papp K.; Puig L.; Nakagawa H.; Spelman L.; Sigurgeirsson B.; Rivas E.; TSEN-FANG TSAI; Wasel N.; Helou S.; Papavassilis C. |
| 臺大學術典藏 |
2020-10-22T07:27:55Z |
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
|
Fox T.; Papavassilis C.; Huang J.; Gong Y.; TSEN-FANG TSAI; Blauvelt A.; Leonardi C.L.; Griffiths C.E.M.; Reich K.; Van De Kerkhof P.C.M. |
| 國立臺灣大學 |
2016 |
Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis: Pooled analysis of 10 phase 2/3 studies
|
Foley, P.; Griffiths, C.; Reich, K.; Leonardi, C. L.; Blauvelt, A.; Mehta, N. N.; Tsai, T. F.; Gong, Y.; Papavassilis, C.; Huang, J.; Fox, T.; van de Kerkhof, P.; 蔡呈芳 |
| 國立臺灣大學 |
2014 |
Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response and Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)
|
Elewski, B.; Lebwohl, M.; Papp, K.; Nakagawa, H.; Sigurgeirsson, B.; Tsai, T. -F.; Tyring, S.; Hampele, I.; Karpov, A.; Helou, S.; Papavassilis, C.; 蔡呈芳 |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
